The therapeutic efficacy of allogeneic hemopoietic stem cell transplantation (SCT) for chronic myeloid leukemia (CML) largely relies on the graft-versus-leukemia (GvL) effect exerted by donor T cells. CD4 þ CD25 high regulatory T cells (T regs ) have been shown to downregulate antitumor responses but their role on GvL has not been evaluated. We performed a crosssectional study in which we enumerated and characterized CD4 þ CD25 high T regs in the peripheral blood of CML patients undergoing allogeneic SCT. We documented higher frequencies of T regs in patients after transplant as compared to normal controls and newly diagnosed patients. The increment was particularly evident in patients who had received their SCT 18 months before. In vitro functional studies demonstrated that the T regs purified from SCT patients exhibited a more potent suppressive activity than T regs isolated from healthy volunteers. Patients in whom T regs numbers were higher than controls more than 18 months after SCT showed evidence of disease relapse. Although the increment in T regs might have an advantageous effect on graft rejection in the early phase post-transplant, our data suggest that T regs exert an inhibitory effect on GvL.
Introduction

Natural regulatory T cells (T regs ) are a subpopulation of thymusderived CD4
þ T cells, which constitutively express the interleukin-2 receptor a-chain (CD25). 1 T regs have initially been described because of their ability to suppress autoreactive T cells in the periphery. 2 They play a crucial role in the maintenance of peripheral tolerance to self and foreign antigens and modulate susceptibility to autoimmune diseases. 3, 4 Apart from CD25, a few other molecules have been used to identify T regs , and they include cytotoxic T lymphocytes (CTL)-associated protein 4 (CTLA-4 or CD152), glucocorticoidinduced tumor necrosis factor receptor 5 and the forkhead box P3 (FoxP3) gene product (reviewed in Sakaguchi and Sakaguchi 6 ). In contrast with murine, human T regs are mainly confined within the fraction expressing high levels of CD25 (CD25 high ). CD4
þ CD25 high cells possess potent immunosuppressive activity and coexpress FoxP3, whereas the CD4 þ CD25 int population contains mainly activated T cells with little or no suppressive function. [7] [8] [9] There is now substantial evidence that T regs play a key role in the control of tumor immunity as well as autoimmunity. Initial studies in animal models showed that the adoptive transfer of CD25-depleted, but not unfractionated, splenocytes could mediate tumor regression in T-cell-deficient athymic nude mice. 10 Accordingly, the reduction of T regs in normal mice, using cell-depleting anti-CD25 monoclonal antibodies before the inoculation of tumor cells, elicited effective immunity, leading to the eradication of the tumor. Therefore, normal immunocompetent hosts contain tumor-reactive T cells whose activation and expansion is suppressed by the presence of T regs . The possibility that this function of T regs may also influence patients with cancer has been suggested by the observation that increased numbers of T regs are present in the peripheral blood and/or tumor microenvironment of patients with solid 8, [11] [12] [13] [14] [15] [16] and hematological neoplasms. [17] [18] [19] The amount of T regs infiltration seems to correlate with bad prognosis in ovarian cancer. 11 Moreover, the use of high-dose IL-2 in melanoma and renal cell carcinoma patients produces a significant decrease of T regs in those who achieve an objective clinical response to IL-2 therapy. 8 Allogeneic stem cell transplantation (SCT) remains the only curative treatment for a variety of malignant hematological diseases. Its efficacy largely relies on the graft versus leukemia (GvL) effect exerted by the donor T cells contained in the stem cell preparation. 20 It has been well documented that the most important factor for relapse is the type of graft-versus-host disease (GVHD) prophylaxis. About 50-60% of patients receiving a T-cell depleted donor stem cell preparation experience leukemia recurrence. However, this cannot be exclusively ascribed to a quantitative difference in the number of potential GvL effector T cells. Active immune regulation or suppression of donor/recipient reactive cells is emerging as a key mechanism for inducing and maintaining unresponsiveness to alloantigens. Accumulating evidence suggests that a balance between immunoregulation and deletion of donor alloreactive T cells can provide effective control of immune responsiveness after organ or cell transplantation. Very little is known about the role of T regs in allogeneic SCT, but it is plausible that similar mechanisms may intervene to modulate the immune responses that follow allografting and potentially affect the beneficial GVL effect. Data obtained in preclinical models have suggested that T regs may preserve the GVL activity, 21, 22 although others have documented tumor progression in the presence of T regs . 23 These discrepancies may be related to the different tumors used and the involvement of different effector cell subsets. 24 Chronic myeloid leukemia is exquisitely sensitive to the GVL activity 25 and can thus provide the best model to test the effect of T regs on GVL. Furthermore, the availability of molecular markers and the development of molecular assays to monitor disease relapse after transplant makes it the ideal setting to evaluate such an association without the interference of a large number of leukemic cells.
We present a cross-sectional study in which we enumerated and characterized peripheral blood CD4 þ CD25 high T regs in 76 chronic myeloid leukemia (CML) patients after allogeneic SCT using phenotypic and functional criteria. We detected a significant expansion of the T reg compartment after allogeneic SCT as compared to normal donors and newly diagnosed CML patients. The frequency of T regs was greater in the early posttransplant period and especially in patients receiving T-cell depletion as part of their conditioning regimen. T regs isolated from post-SCT patients exhibited a higher in vitro suppressive activity as compared to those from normal donors. We observed a statistically significant association between increased levels of T regs and leukemia relapse, thus suggesting that T regs might impair the clinical GvL effect.
Materials and methods
Patients
We carried out a cross-sectional study on 76 patients who underwent allogeneic SCT for CML in chronic phase during a 15-month period from April 2004 to July 2005 in the Department of Haematology at the Hammersmith Hospital. The conventional conditioning regimen was cyclophosphamide (Cy) and total body irradiation at a dose of 13.2 Gy or 14.4 Gy in the case of sibling (SIB) or volunteer unrelated donors (VUD), respectively. Reduced intensity conditioning (RIC) regimens consisted of fludarabine, melphalan and Cy. All patients receiving a VUD as well as all but two of those undergoing RIC were in vivo T-cell depleted with Campath-1H (anti-CD52). Standard SCT received cyclosporine and methotrexate as GvHD prophylaxis, RIC-SCT cyclosporine alone. Acute and chronic GvHD were assessed according to the Seattle criteria. 26, 27 Twenty-one blood samples from newly diagnosed CML patients in chronic phase and 20 from healthy volunteers were used as controls. Normal volunteer samples were either fresh blood samples obtained from healthy volunteers or buffy coats from single blood donations. All samples from newly diagnosed CML patients were from leucapheresis collection at diagnosis. In nine cases, they had been frozen before being used in the analysis. All patients and volunteers had given informed consent.
Flow cytometry
Peripheral blood mononuclear cells (PBMC) were isolated from ethylenediaminetetraacetic acid blood samples by Ficoll density gradient centrifugation, counted and simultaneously stained with a combination of three or four of the following antibodies: CD3-fluorescein isothiocyanate (FITC), CD8-APC, CD4-FITC, CD4-PerCP, CD25-PE, CD62-L-FITC, CD69-APC, CD127 (a subunit of the IL-7 receptor), and the correspondent isotype controls (all antibodies from BD Pharmingen, Oxford, UK). Samples were acquired using a fluorescence-activated cell sorting (FACS)Calibur cytofluorimeter (Becton Dickinson, San Jose, CA, USA) and analyzed with the Cell-Quest software (BD Biosciences, UK). A minimum of 5 Â 10 4 gated events were acquired per sample. Figure 1 shows the gating criteria used to define the CD4 þ CD25 high or T regs population in all samples. T regs were given as a percentage of total CD4 þ T cells. Total cell numbers for the different populations were calculated from the lymphocyte count given by the full blood count performed on the same sample. For FoxP3 and CTLA-4 expression analysis, cells were permeabilized after surface staining and then incubated with FITC-FoxP3 (clone PCH101, eBioscience) and/ or PE-CTLA-4 (Pharmingen, Oxford, UK). Isotype controls were performed for each sample.
BCR-ABL real-time PCR
Samples analyzed for T regs content were simultaneously investigated for minimal residual disease at each follow-up. Real-time polymerase chain reaction for BCR-ABL was performed as described before from unfractionated blood samples. 28 Levels of BCR-ABL were normalized to ABL expression and expressed as BCR-ABL/ABL ratio. Samples were analyzed in replicates of three, and in all cases the number of ABL copies was at least 1 Â 10 4 . Molecular remission was defined as BCR-ABL/ABL ratio of 0.02% or less on two or more occasions, whereas relapse, was defined as three consecutive values greater than than 0.02% or two consecutive values greater or equal to 0.05%. 29 In all patients defined in molecular relapse the BCR-ABL/ABL ratio was increased in subsequent samples.
Cell purification
CD4
þ CD25 þ and CD4CD25 À populations were isolated from heparinized peripheral blood (PB) samples following a two-step procedure. The first step involved CD4 isolation by depleting cells expressing CD8, CD16, CD19, CD36, CD56, CD66b and glycophorin A using a commercially available kit (Rosette Sep, T regs and leukemia relapse E Nadal et al
Stem Cell Technologies). CD4
þ isolated cells were then incubated with CD25-coated magnetic beads (Dynal) at a bead:CD4 þ cell ratio of 4:1 for 30 0 at 41C in a rotor. After collecting the CD4 þ CD25 À subset from the supernatant, the beads were gently washed three times and the final population, containing mainly CD4 þ CD25 high þ cells, was incubated on a shaker for 2 h with Detachabead (Dynal) and washed after being separated from the beads. After selection, the purity of the different populations was checked by FACS analysis. The CD3 þ CD4 þ purity was consistently 495%. The CD4 þ CD25
À and CD4 þ CD25 þ showed a purity of 89-94 and 85-95%, respectively.
Functional assay
The inhibitory activity of purified CD4 þ CD25 þ was evaluated by a conventional suppressive assay based on their effect on CD3/CD28 induced T-cell proliferation. Briefly, 5 Â 10 
Statistical analysis
Clinical characteristics that may influence T regs frequencies were compared using the Mann-Whitney test. For comparison between categorical variables, a w 2 or Fisher test was performed. A forward stepping multiple regression analysis was used to study clinical variables with Po0.20 from the univariate analysis of T regs frequencies. A logistic regression was performed to analyze the relationship between disease status and different transplant variables. T regs values were included either as a continuous variable or dichotomized using a cutoff of 0.87% (the median value obtained in healthy volunteer samples). Data were analyzed using the statistical package SigmaStat for Windows 3.0.1 (SPSS) and Sigma XL. All quoted P-values are two-sided, with Po0.05 being considered statistically significant.
Results
Patients
We analyzed 76 samples from 76 patients attending the outpatient clinic for follow-up after SCT. Table 1 summarizes their clinical characteristics. All transplants were performed at a single center. At the time of the study, all patients were more than 100 days post-transplant, and 28 of them (37%) had symptoms of cGvHD, in 17 cases limited and in 11 extensive. Three patients had developed cGvHD after DLI (one limited, two extensive). Thirty-three patients had received DLI for leukemia relapse; 24 of them were in remission at the time of the study. Among the other 43 patients, 20 were in complete molecular remission, whereas 23 were in molecular relapse.
CD4
þ CD25 high post-transplant exhibit the phenotype and function of regulatory T-cells (T regs )
The percentage of CD4 þ lymphocytes expressing very high levels of CD25 was determined according to the gating criteria shown in Figure 1a . CD4 þ CD25 high thus gated, exhibited a regulatory phenotype in both normal donors, and patients: CD62-L positive (median 87%723), CD69 low positive (median 39%723) and CTLA-4 positive (median 95%714). Intranuclear staining for Fox-P3, performed in 13 samples from post-SCT patients and two from normal donors confirmed that the CD4CD25 high population defined by our gating criteria highly expressed FoxP3 (median 81.8%711). FoxP3 was absent in the CD4CD25 À subset (median 3.7%72) in accordance with previous reports. 30 Such phenotype was confirmed on purified CD4
þ CD25 þ cells that showed coexpression of Fox-P3, CTLA-4 and CD62-L, whereas CD69 was negative; the CD4 þ CD25 expression includes almost all Fox-P3 þ T regs . 31, 32 T regs , defined by our criteria, were examined for these parameters. We analyzed samples from 14 patients after SCT and two normal healthy volunteers, and found a very good correlation between (Figure 2 ).
Most importantly, purified CD4 þ CD25 þ from both patients and donors exerted a dose-dependent suppression on the CD4 þ CD25 À proliferation (see below). Therefore, based on these phenotypic and functional characteristics, we can define the CD4 þ CD25 high cells enumerated here as T reg cells.
CD4CD25 high T regs are increased following allogeneic SCT
Patients after allogeneic SCT showed a higher proportion of T regs when compared with normal controls (median 1.5 vs 0.87%, P ¼ 0.004), despite the reduced percentage of the total CD4 þ population in the post-transplant samples as compared with normal volunteers (median 25 vs 41%, Po0.00001) (Figure 3 ). No differences were found in the CD8 þ CD3 þ population (median 25.9 vs 25.4%, P ¼ NS). Interestingly, the analysis of the newly diagnosed CML patients showed that not only was the T regs frequency markedly reduced as compared with patients post-SCT (median 0.27 vs 1.5%, P ¼ 0.00003) but also in respect to normal volunteers (median 0.27 vs 0.87%, P ¼ 0.03). Our findings confirm that T regs have a selective growth advantage in a lymphopenic environment, as previously reported. 33 Although post-SCT patients also tended to have higher absolute numbers of T regs , this difference was not statistically different (4.55 Â 10 6 /l vs 3.24 Â 10 6 /l, P ¼ NS).
Post-SCT T regs exhibit a higher immunosuppressive activity than T regs from normal individuals
In eight post-SCT patients, CD4 þ CD25 high were purified for functional characterization and compared with normal T regs from six healthy volunteers ( Figure 4 ). As expected, both normal and patient T regs were anergic upon TCR stimulation, but those isolated from patients showed a significantly higher immunosuppressive function when cocultured with their CD4 þ CD25
À counterparts even at very low concentrations. Therefore, post-SCT patients not only showed an increased frequency of T regs in their peripheral blood, but the T regs exhibited a higher immunosuppressive activity in vitro as compared with those from healthy volunteers.
Factors influencing T regs expansion postallogeneic SCT
The percentage and numbers of T regs detected in the PB of 76 post-SCT patients were analyzed with respect to different clinical transplant variables. In our series, a total of 28 patients had signs of cGvHD at the time of the study. The median T regs value in patients with limited cGvHD was not different from those without signs of cGvHD (median 1.34 vs 1.36%, P ¼ NS); although those with extensive cGvHD had higher levels, the difference was not statistically different (median 1.93%, P ¼ 0.1) (Figure 5a ). The median time from SCT in our 76 patient series was 35 months (range 3-225). In agreement with other reports, we observed that T regs frequencies are higher in the early post-SCT period. Patients who received an allograft up to 18 months T regs and leukemia relapse E Nadal et al before the sampling showed significantly higher frequencies of T regs when compared with those who were transplanted more than 18 months before the analysis (median 1.96 vs 1.29%, P ¼ 0.016) (Figure 5b ). Noticeably, patients who had received Tcell depletion as a GvHD prophylaxis showed an even greater increase of the T reg compartment in the earlier post-transplant period (o18 months) in comparison to the later period (median 4.25 vs 1.43%, P ¼ 0.018). However, the absolute T reg numbers were not significantly different between the two groups (4.2 vs 4.6, P ¼ NS).
The univariate analysis (Table 2) showed that, apart from the time post-SCT, the other factors that correlated with a higher frequency of T regs were the use of a RIC regimen, male recipients receiving a female graft and, most interestingly, patients in leukemia relapse. However, in the multiple regression analysis only the time post-SCT and disease status (molecular remission versus relapse) were associated with an increase in T regs values (P ¼ 0.004 and 0.020, respectively). In a logistic regression analysis using a T regs cutoff value of 0.87%, only relapse was associated with an increased risk of elevated values (RR 5.8, P ¼ 0.025). An analysis using data from 43 patients who had not received DLI showed similar results (data not shown).
T regs and disease relapse
As all patients were transplanted for CML, we were able to monitor the disease at the molecular level and examine the relationship between relapse post-SCT and peripheral blood T regs numbers. The interesting fact that those patients in remission had significantly lower T regs frequencies than those in relapse (median 1.09 vs 1.9%, P ¼ 0.017) (Figure 5c ) prompted us to analyze their predictive value for relapse in the 43 patients who had not received DLI after SCT. As represented in Figure 6 , those patients in molecular relapse not only had doubled frequencies of T regs when compared with those in molecular remission (median 1.96 vs 0.81%, P ¼ 0.002) but also had significantly higher T regs absolute numbers (5.3 Â 10 6 vs 3.0 Â 10 6 /l, P ¼ 0.016) despite the fact that CD4 lymphocyte numbers were lower in the relapse group (17.4 vs 23.7%, P ¼ NS and 223 Â 10 6 vs 335 Â 10 6 /l, P ¼ NS). The univariate analysis for factors associated with remission/relapse showed that only T regs percentage or absolute numbers were statistically significant. The logistic regression analysis confirmed that T regs (taken either as a continuous or categorical variable) was the only predictive variable for relapse (exp 1.44, P ¼ 0.011) ( Table 3) . Although GVHD and T-cell depletion are the major factors for relapse, these variables were not found to correlate with disease status in this cohort of patients.
Discussion
Allogeneic SCT is associated with a network of immune responses, between the donor and the recipient, which mediate graft rejection, GVHD and the beneficial GVL effect. Although the histocompatibility differences are primarily responsible for these reactions, other components involved in the preparatory regimen have a prominent role too. In fact, donor hematopoietic stem cells transplanted after a myeloablative conditioning regimen are subject to a homeostatic expansion that eventually leads to the reconstitution of recipient haematopoiesis. 34 This process also involves the T-cell lymphoid compartment in which subpopulations repopulate at different pace. Studies of immune reconstitution after SCT have shown that NK cells and CD8 þ lymphocyte numbers recover in the first few months, whereas the CD4 þ subset takes over a year to reconstitute, and in some cases never reaches the pre-transplant levels. 35 In our study, we have documented an increase in CD4 þ CD25 high compartment in the early post-SCT despite severely reduced total CD4 þ lymphocytes. Such a trend had already been observed by Clark et al. 36 The notion of an advantageous expansion of this subset is further supported by the fact that, during the earlier period, we observed even higher frequencies of T regs in patients receiving a T-cell depleted SCT. This would be in accord with a recent study showing a selective T regs and leukemia relapse E Nadal et al increase of CD4 þ CD25 high T regs in lymphopenic patients after they received a single dose of Campath for multiple sclerosis. 33 The fact that we did not find significant differences in absolute numbers merely reflects the overall CD4 reduction in these patients. Our data suggest that, after myeloablation, conventional CD4 þ do not expand at the same rate as CD4 þ CD25 high . The correlation between regulatory activity and high homeostatic expansion has been proposed to reflect the avidity for selfpeptide:MHC complexes. 37 However, the release of IL-2 and TNFa produced during the cytokine storm following the conditioning regimen may also contribute to the initiation of T regs amplification in early stages post-SCT, together with concurrent infections, which could favor a preferential T regs expansion via toll-like receptor activation. 38 T-cell recovery involves not only peripheral homeostatic expansion of donor infused cells, but also de novo generation through the thymus, which is essential to restore the new T-cell repertoire after SCT. 39, 40 The thymus derived subset of CD4 þ CD25 high or T regs has been demonstrated to be a key player in T-cell homeostatic regulation controlling the expansion and/or function of other T-cell pool sizes. 41 After allogeneic SCT, thymic function can be severely impaired, but it has been also shown that T regs can independently expand in the periphery. Therefore, the immune responses following transplantation may be influenced by changes affecting this regulatory subset. Although before 18 months this expansion seems to globally affect all the patients irrespective of their disease status, later on, when the TCR repertoire is more likely to be reconstituted, 40 we observed a strong statistic correlation T regs and leukemia relapse E Nadal et al between molecular relapse and T regs increase. Unexpectedly, the correlation between T regs and loss of GVL effect was not paralleled by a reduction in GvHD. However, all the studies published so far in the transplant setting intending to correlate T regs with the incidence of GvHD have led to controversial results. 36, [42] [43] [44] [45] Although this could reflect the heterogeneity in the underlying diseases and the different criteria used to define human T regs , two alternative explanations could be provided. The first is that in these patients the level of increase in T regs is sufficient to inhibit the GVL, but not the GvHD. This notion would be supported by the fact that a lower number of alloreactive donor T cells are required to produce GVL as compared to GvHD. 25 Therefore, the number of T reg may be of fundamental importance in the therapeutic setting. In this regard, the quantity of T regs used to prevent GvHD in animal models 23, 46 was substantially large and far from clinical reality (T regs /T conventional ratio 1:1). Our data are apparently in contrast with the selective effect of T regs on GvHD described in animal models, but noticeably in all cases, T regs were generated ex vivo and transferred in large doses using MHC disparate combinations between donor and recipient. 21, 23 Furthermore, an acute GvHD model was used. An alternative but complementary explanation to this lack of correlation between T regs , GVL and GvHD is that T regs may be dislodged to the peripheral tissues where the inflammation takes place rather than circulating in the peripheral blood. 47 This hypothesis of specific site could also explain why the observed T regs increase was even more evident when compared to the baseline levels of T regs in untreated chronic phase CML patients. To explain the low levels of T regs in the peripheral blood of untreated CML patients, a plausible hypothesis could be that T regs are displaced to the bone marrow, which is the site of the leukemic stem cells in CML. In this regard, it has been reported that T regs are increased locally in some solid tumors. Thus, high numbers have been found in lung tissue and in ascitic fluid in patients with lung and ovarian cancer, respectively. 11, 14 The use of T regs quantitation to predict disease relapse after transplant needs to be validated in larger longitudinal series, and could be a promising tool in those diseases in which a reliable molecular marker is not available. Although different forms of GVHD immunoprophylaxis influence T-cell reconstitution and GVL, and may have impacted on the outcome of our study, we suggest that variations in the size of T reg pool contribute to leukemia relapse. Therefore, strategies aiming at controlling Tcell homeostasis may prove helpful in preventing relapse after the transplant. 
